ACTL6A and esophageal cancer: Presently, there are no available studies on evaluating the dose-dependent expression of ACTL6A. However, ACTL6A has been applauded as a novel gene responsible for cisplatin resistance in various cancers, such as ovarian, lung, and esophageal cancers (Xiao et al., 2021).